Search
Supernus Pharmaceuticals Inc
SUPNAdd to Watchlist
44.630USD
-0.980-2.15%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.59BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Supernus Pharmaceuticals Inc is 8.33, ranking 41 out of 155 in the Pharmaceuticals industry. The average price target is 61.50, with a high of 65.00 and a low of 50.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
63.500
Target Price
+42.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Supernus Pharmaceuticals Inc
SUPN
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Supernus Pharmaceuticals Inc's expected revenue for the next quarter?
Supernus Pharmaceuticals Inc's expected revenue is 204.96M.
What is Supernus Pharmaceuticals Inc's price target?
Analysts forecast that Supernus Pharmaceuticals Inc's price target is USD 61.50, with the highest forecast at USD 65.00 and the lowest forecast at USD 50.00.
How have Supernus Pharmaceuticals IncSUPN's recent earnings per share performed?
The market expectation was USD -0.04, while Supernus Pharmaceuticals IncSUPN's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD 0.42.
What is the analyst rating for Supernus Pharmaceuticals Inc?
Based on the ratings of Supernus Pharmaceuticals Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.